B+
Bull case
25%
Probability
Target price
$185.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
RGEN
RepligenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$120.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
+68.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.9
Score
AI commentary
The post-earnings tone is initially constructive: Investing.com reported a 3.4% pre-open gain after the earnings beat, guidance increase, and Benchmark upgrade. Follow-through was mixed, however, with the latest live price at $141.69 below the $143.60 July 30 anchor. Broader analyst reaction remains unavailable, and social, options, short-interest, and employee-sentiment data are not available; maintain a monitoring stance.
RankAlpha Sentiment Codex - 2026-07-31
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-15catalystQ2 beat and raised FY26 guidance support near-term revisionsMedium impact
Q2 revenue rose 12% reported and 13% organically; adjusted EPS was $0.54 versus $0.37, and management raised FY26 organic-growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09 [#SEC-8K-2026-07-28]. Investing.com reported adjusted EPS above a $0.45 consensus estimate and a Benchmark upgrade to Buy with a $185 target: https://www.investing.com/news/stock-market-news/why-is-repligen-stock-rallying-today-93CH-4816935.
2026-10-29eventBioLife Solutions acquisition closing and integrationHigh impact
Repligen agreed to acquire BioLife Solutions for approximately $1.5 billion, funded 64% with stock and 36% with cash. Management expects the transaction to be accretive to growth, margins, and adjusted EPS, but closing timing was not disclosed and execution remains material [#SEC-8K-2026-07-22].
2027-07-31catalystCell-therapy consumables expansionHigh impact
BioLife adds a commercial-stage, recurring-revenue biopreservation platform and broader cell-processing exposure. Longer-term upside depends on transaction completion, integration, and sustained cell-therapy demand rather than a near-term clinical milestone [#SEC-8K-2026-07-22].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology